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Percutaneous closure of  
the patent foramen ovale:  
A cardiological perspective
Venous flow is channelled towards the fossa ovalis due to the 
orientation of the inferior vena cava. A prominent Eustachian valve 
is commonly observed in the presence of a PFO. This may further 
direct inferior caval flow towards the fossa ovalis. 
Department of Paediatric Cardiology, University of the Free State, 
Bloemfontein, South Africa
Address for correspondence: 
Prof S.C. Brown
Department Paediatric Cardiology G69
University of the Free State
PO Box 339
Bloemfontein
9300
South Africa
Email: 
gnpdscb@ufs.ac.za
S.C. Brown AbstrAct
264
PAtEnt 
forAmEn ovAlE
IntroductIon                                                              
Until recently, the patent foramen ovale (PFO) was considered a 
foetal remnant and of limited clinical importance. It has now been 
recognised that patency of the foramen ovale results in problems 
exclusively encountered in adults, especially stroke and migraine. 
Improvements in methods of closure and diagnosis have become 
available for clinical practice and focused renewed attention on the 
risks and management of patients with a PFO.
AnAtomIcAl Issues                                                     
In a healthy population, up to 27% may have a PFO.(1,2) PFOs are 
anatomically more complex than atrial septal defects and consist 
of two anatomically and dynamically different components – a thick 
rigid septum secundum and a thin mobile septum primum.(3) Lack 
of fusion of these two structures results in a patent foramen. The 
length of the tunnel formed by this interaction is determined by 
the extent of overlap, whilst the width (diameter) is determined by 
the area of non-fusion between these two components (Figure 1). 
Atrial septal aneurysms are frequently associated with PFOs and 
may bulge into either the left atrium, right atrium or both atria. 
A patent foramen is commonly found in the general popu-
lation. evidence exists that a patent foramen ovale (PFo) and 
atrial septal aneurysm are strongly associated with crypto-
genic stroke. Associations with migraine have also been 
described, but the status of cause and effect is less clear. 
management of PFo is controversial and no form of therapy 
has been properly evaluated. PFo closure devices are readily 
available and can be safely and effectively implanted per-
cutaneously. complication rates are low and symptoms are 
improved in most patients. At present, there is a lack of 
guidelines for the treatment of PFo and results of prospective 
randomised trials are eagerly awaited. SAHeart 2010; 7:264-271
FIGure 1: three Dimensional tEE demonstrating Pfo anatomy: 
the thick septum secundum can be seen (arrow A) overlapped by 
the thin septum primum (arrow B). A guide wire (white arrow) is 
demonstrated passing through and lifting the long channel, exiting 
at the opening in the left atrial aspect due to lack of fusion of the 
septum primum and secundum. 
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All of these factors should be taken into consideration during 
diagnosis and closure of a PFO. Rigid devices not taking the dyna-
mic interaction of the septae into consideration may “splint” the 
defect and result in either incomplete epithelialisation or residual 
shunting. Diagnostic consideration should also be given to anato-
mical and physiological factors. For example, the presence of a 
prominent Eustachian valve may have an influence on the demon-
stration of a PFO since contrast injection in the veins of the upper 
limbs may not yield a positive bubble test due its effect on direction 
of flow, whilst it may show a large shunt in the same patient if 
injected via a lower limb vein. Device struts may also be caught in 
the Eustachian valve, preventing successful closure. The patent 
foramen ovale is clearly a complex structure and attention should 
be paid to the anatomical substrate during diagnosis and pecutaneous 
management of the PFO since it may have a profound influence on 
risks and outcomes.(4)
detectInG A PFo                                                        
transthoracic Echocardiography (ttE)
TTE is generally used as a screening test to diagnose PFO and it is 
important to recognise that a negative TTE does not rule out a 
PFO. In patients with good echocardiographic windows, anato- 
mical detail of the PFO may be delineated. However, even with 
harmonic imaging, it has lower sensitivity and specificity (76.5% and 
79.4%, respectively) than transoesophageal echocardiography.(5,6) 
Using the Valsalva manoeuvre alone or in combination with agi-
tated saline or other contrast agents, results for detection of PFO 
by means of  TTE can be markedly improved.(7-10) 
transcranial Doppler (tCD)
TCD is highly sensitive and specific for the diagnosis of right to left 
shunts and is the preferred screening tool.(11) TCD does not cause 
any discomfort to patients and requires no sedation. However, 
TCD does not differentiate PFO from other causes of right to left 
shunts (e.g. arteriovenous fistula) neither does it provide any 
information regarding anatomy or especially, the presence of an 
atrial septal aneurysm.(12) 
transoesophageal Echocardiography (tEE)
TEE is considered the gold standard for the diagnosis of PFO and 
delineation of the underlying morphology (Figure 2). It is more 
invasive than the other methods of detection and patients need 
to be sedated. Contrast echo, with or without the Valsalva mano-
euvre, is helpful in the assessment of a PFO. Bubbles can be seen 
crossing the PFO during the release phase of the Valsalva mano-
euvre as blood kept out of the thorax rushes back into the right 
atrium. TEE is especially helpful to ensure accurate and safe place-
ment of transcatheter devices. In patients with cryptogenic stroke, 
it is recommended that TEE should routinely be included in the 
assessment of such patients since it also allows other cardiovas-
cular causes of stroke to be detected.(13-15)
FIGure 2: tEE images of Pfo. In A, a long tunnel-like Pfo is demonstrated with a thin septum secundum overlapping (arrow) a thick septum 
secundum. B shows an atrial septal aneurysm with multiple perforations (arrows).
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Overall, there is a lack of standardisation of methods to demon-
strate size and significance of PFOs as well as quantification of the 
shunt. The number of contrast bubbles in the left atrium is some-
times employed, but does not necessarily correlate with the 
magnitude of the shunt.(16-18) Furthermore, superior caval flow, 
which is directed towards the tricuspid valve may be prevented 
from crossing a PFO due to the effect of Eustachian valve stream-
ing which influences the reliability of detection of a PFO’s shunting 
and the injection of echocardiographic contrast into a lower limb 
vein may prove more accurate.(19,20) Also, since patients are 
commonly sedated to perform TEE, the Valsalva manoeuvre may 
be difficult to perform. The classification of atrial septal aneurysm 
also varies, but tissue movement in excess of 10mm from the 
septal plane is helpful in the diagnosis.(21-23) Atrial septal aneurysm 
is frequently associated with PFO as well as other cardiac abnor-
malities.(24,25) Other imaging modalities such as intra-cardiac echo-
cardiography (ICE) are sometimes employed during implantation 
of devices, although most operators still prefer TEE.
PFo And stroke                                                          
Stroke is one of the leading causes of morbidity and mortality 
worldwide. Cryptogenic stroke accounts for up to 40% of causes 
of ischaemic stroke and is essentially diagnosed if, after extensive 
investigation, no other cause of infarction can be identified.(26) 
The exact mechanism by which PFO causes stroke is ascribed to 
paradoxical embolism by way of a right to left shunt. The vast 
majority of studies have reported an increased prevalence of PFO 
ranging from 31-77% in patients with cryptogenic stroke compared 
to less than 25% in patients with stroke of known cause.
The presence of an atrial septal aneurysm increases risk: PFO with 
atrial septal aneurysms occurred significantly more (odds ratio 3.65; 
95% CI: 1.64-8.13) in patients than in controls.(27-30) Although this 
association with stroke has been more convincingly established in 
patients younger than 55 years of age, recent studies have also 
demonstrated significant associations in older patients.(13,28,31,32) 
In addition, a recent publication illustrated that the co-existence of 
a PFO with atrial septal aneurysm play an important pathogenic 
role in the severity of white matter lesions in these patients (odds 
ratio 2.4; 95% CI: 1.11-5.17) compared to stroke patients without 
septal abnormalities (p = 0.026).(33) The presence of both PFO and 
atrial septal aneurysm is also a significant predictor of an increased 
risk for recurrent stroke – hazard ratio 4.17 (95% CI: 1.47-11.84) 
with a risk of 15.2% compared to 4.2% in the absence of both.(16) 
TEE is thus recommended for all patients with cryptogenic stroke 
to identify PFO or other cardiac causes.(14,15)
results oF trAnscAtheter closure In                
IschAemIc stroke
Currently, due to a lack of appropriate randomised controlled 
clinical trials, no ideal treatment (medical, surgical or percutaneous 
device implantation) can be recommended. There is also insuffi-
cient long-term follow-up data. Several reports have demonstrated 
the feasibility of percutaneous closure. Small studies, as well as 
systematic reviews, showed that recurrence rates for stroke after 
device closure was reduced to between 0 and 5% (versus 3-12% 
with medical therapy) with minimal residual shunting.(10,34-36) 
Interestingly, some of the recurrent ischaemic episodes occurred 
in patients where no residual shunts could be detected, prob- 
ably indicating that other underlying mechanisms are involved in 
the pathogenesis of stroke.
At present, there are no clearly defined guidelines from any 
professional society and most state that insufficient evidence exists 
to make a recommendation.(37) The American Heart Association, 
American Stroke Association and American College of Chest 
Physicians as a result encourage physicians to participate in ongoing 
trials (RESPECT, CLOSURE-1, PC-Trial, CLOSE and Gore REDUCE) 
to resolve the uncertainties regarding optimal care for these 
patients.(28,38)
mIGrAIne And PFo                                                      
Right-to-left shunts are more prevalent in patients with migraine. 
Migraine also occurs more commonly in patients with right-to-left 
shunt lesions. In addition, PFOs have been demonstrated in 40-72% 
of those with migraine. The odds of a patient with migraine having 
a PFO are 2.5 times greater than the general population and for 
migraine with aura 3.2 times greater than those without aura.(39-42) 
Several retrospective, non-randomised trials suggested benefit 
following PFO closure. However, the only prospective, sham 
controlled trial (MIST-I) showed negative outcomes for both the 
primary and secondary endpoints of improvement of migraine 
headaches.(43) It was concluded that the role of PFO closure for 
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the treatment of migraine was unclear. Differences between MIST-I 
and other studies should be mentioned. Only migraine with aura 
without history of previous embolic episodes was included, whilst 
the majority of other studies included patients with migraine and 
history of embolic stroke. Patients treated in MIST-I all had severe 
refractory migraine not responding to any other form of treatment 
and there were controversies regarding the methods of follow-up 
assessment as well as absence of data regarding the concomitant 
use of medication. 
A current systematic review and meta-analysis of 1 306 patients 
showed complete cure of migraine after PFO closure in 46% (95% 
CI: 25-67%) with resolution or significant improvement in 83% 
(95% CI: 78 -88%).(44) Similar findings have recently been reported 
and it has been shown that migraine with aura and high pain 
intensity at baseline were independent predictors of positive 
response to PFO closure. The study included patients with and 
without history of paradoxical embolism.(45) There are ongoing 
randomised trials, including percutaneous closure of PFO in migraine 
with aura (PRIMA) and the prospective randomised investigation 
to evaluate incidence of headache with migraine and PFO using 
the Amplatzer PFO occluder compared to medical management 
(PREMIUM).
dIvInG And PFo                                                           
Neurological decompression events occurring when diving with a 
PFO are reported to have an odds ratio of 2.6 with PFO present in 
60% of patients vs. 36% in controls. A TEE should be performed 
in divers when no cause is evident after a neurological decompres-
sion incident.(46,47) It is recommended that, if a diver wants to 
continue diving after a PFO is detected following such an incident, 
other safety measures including the option of percutaneous device 
closure, could be considered.
PercutAneous PFo closure                                   
The initial devices used for closure of PFO were based on versions 
of atrial septal defect closure devices. Various devices have been 
employed worldwide, but in South Africa the Amplatzer® (AGA 
Medical, MN, USA), Atriasept II® (Cardia Eagan, MN, USA) and 
Solysafe® (Swissimplant AG, Solothurn, Switzerland) devices are 
available in different diameters (Figure 3). PFO anatomy produces 
FIGure 3: Pfo closure devices from left to right are: Atriasept II®, Amplatzer® and Solysafe®.
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unique challenges and appreciation of these characteristics play an 
important role in the selection of a device. 
Procedure                                                                      
Technical details have been published but generally it is a relatively 
simple and quick procedure.(29,35,48-50) In short, percutaneous 
venous access is gained via the femoral vein and an appropriate 
long sheath is left in situ after having crossed the PFO into the left 
atrium. Patients are heparinised and extreme care should be taken 
to prevent air embolism throughout the procedure. Prophylactic 
antibiotics are usually given. The procedure may be performed with 
or without general anaesthesia using one or more of the following 
for control: fluoroscopy, TEE or ICE. Most operators prefer general 
anaesthesia and use TEE combined with fluoroscopy. Careful 
consideration should be given to the morphology of the PFO and 
surrounding structures when selecting the type and size of a device. 
Balloon sizing may be required, but this is not generally neces-
sary.(51,52) Presence of atrial septal aneurysms and prominent 
Eustachian valves may complicate procedures. After selection of an 
appropriate device, it is deployed in the correct position. Most 
devices are retrievable and re-useable before release from the 
delivery mechanism. The device is then released and some are 
even retrievable at this stage (Figure 4). Patients may be discharged 
on the same day after satisfactory positioning has been confirmed 
(Figure 5). Clopidogrel is usually prescribed for 4-6 weeks and low 
dose salicylates for 6 months. Follow-up TEE should be performed 
6 months after implantation of a percutaneous PFO device.
Success rates for the procedure range from 98-100%. In expe- 
rienced centres with experienced operators, complications are 
uncommon but minor complications (pain, bleeding at site of 
catheterisation, transient arrhythmias etc.) occur in up to 7.9% 
and major complications (tamponade, infection, thrombus forma-
tion) in less than 1.5% of cases respectively.(10, 41,42, 53, 54) Late ero-
sions into surrounding tissues have been described with all intra-
cardiac devices, but are rare after PFO closure. Residual shunts 
are common immediately following implantation, but infrequent 
(5-10%) after 12 months.(35, 55, 56)
more recent trends                                               
Three-dimensional echocardiography may provide improved 
assistance during assessment, implantation and follow-up of 
device closure of defects (Figure 6). New devices are being 
developed specifically for PFO closure – these are less rigid and 
bulky and should lead to improvement in closure rates with a 
reduction in complications.(57) Future devices will probably employ 
less material and metal and target the specific anatomical defect.
controversIes And Food For thouGht                 
Percutaneous closure of a PFO can be safely and effectively 
performed using modern devices. However, the indications for 
closure are more complex and will be debated for many years to 
come. Most of the uncertainties are caused by insufficient evidence 
attributable to the lack of randomised, controlled clinical trials. This 
is aggravated by the slow recruitment in currently ongoing trials. 
Literature comparing medical and percutaneous management is 
not available and current opinion is based on observational studies 
and case-control reviews with its inherent drawbacks. 
Compelling evidence exists that PFO with atrial septal aneurysm 
carry considerable risk. It is more difficult to quantify this risk in the 
presence of a PFO. The question of cause and effect is still unclear 
and therefore double standards in management exist.(58-61) Most 
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FIGure 4: Atriasept II® device with cable of delivery forceps still 
attached (A) and after release (B). Amplatzer® Pfo device attached 
to delivery cable pre-release (C) and after release (D).
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likely, many different mechanisms are involved in causing stroke 
and migraine in the presence of a PFO and probably PFO closure 
may benefit only certain subsets of patients. Decisions we make 
now have an effect upon the future and, as treating physicians, we 
could end up in difficult situations: We could close defects un-
necessarily with the risk of complications while having little effect 
on prevention of stroke; or alternatively delay closure and face 
medico-legal risks due to “malpractice” in future years. Add to this 
a patient who had a stroke and knows that there is a “hole” in 
his/her heart and one can understand that it makes for an emo-
tional debate.
It is also important to recognise what effects rigid devices may 
have on intra-cardiac structures. In a thought provoking editorial, 
McElhinney pointed out that studies have shown aortic regurgita-
tion, erosion and atrio-ventricular block with intra-cardiac devices, 
sometimes many years after implantation due to the interaction of 
the devices with the surrounding tissues. He postulated that the 
FIGure 5: tEE showing good position of Pfo device with stabilization of atrial septal aneurysm and no residual leaks. 
FIGure 6: three Dimensional tEE image of Pfo closure device: 
left atrial disk of closure device in good position against inter-atrial 
septum.
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future of PFO closure may hinge on these considerations more 
than other.(62)
At present it seems that PFO closure may be of benefit, although 
unproven, in patients with PFO and atrial septal aneurysm with a 
history of: cryptogenic stroke (especially if <55 years); recurrent 
deep vein thrombosis and pulmonary embolism; existence of 
contra-indications to anticoagulation; large shunts; and in com-
mercial divers. These are only suggestions and not recommenda-
tions or guidelines. It also emphasises the need for societies to 
provide clear guidelines to assist treating physicians and bring 
“closure” to this matter.
conclusIon                                                                   
PFO is a common congenital anomaly in the general population. 
In contrast to previously held beliefs that a PFO is an innocent 
anomaly, it has been found to be more prevalent in patients with 
cryptogenic stroke and certain forms of migraine. No optimal 
therapy for PFO in these patients, either medical or interventional, 
has been identified and future clinical management will depend on 
clarification of the pathogenesis related to these conditions. Per-
cutaneous closure of a PFO is relatively simple. The devices have 
been shown to be effective and safe. Evidence for best treatment is 
lacking and results of randomised, controlled clinical trials are 
eagerly awaited. 
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